mild cognitive impairment
Conditions
Interventions
The treatment group will receive oral administration of reduced coenzyme Q10-containing soft capsules once daily.
The placebo group will receive oral administration of reduced coenzyme Q10-free soft c
Sponsors
KAKU Neurosurgery clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Age at the time of giving informed consent: 50 to 89 years (2) Diagnosis: mild cognitive impairment or mild Alzheimer's-type dementia (3) Patients should have an adequate understanding of the objectives and details of this study and the ability to give written informed consent for participation in the study either by themselves or via their respective legal representative.
Exclusion criteria
Exclusion criteria: (1) A score of 19 or less on the Revised Hasegawa Dementia Scale (HDS-R) (2) Diagnosis of Parkinson's disease, Huntington's disease, multiple sclerosis, or epilepsy or the presence of head trauma (3) Diagnosis of schizophrenia, depression, or serious heart disorder; incomplete recovery from a malignancy; or ongoing dialysis (4) Treatment with oxidized coenzyme Q10 or reduced coenzyme Q10 within the last 2 months (5) Judgment by the investigator as being ineligible to be a study subject for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the Mini-Mental State Examination (MMSE) score before and after ingestion of the test food | — |
Countries
Japan
Contacts
Public ContactSatomi Nakano
Bell Medical Solutions Inc. Clinical Research and Development
Outcome results
None listed